Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Cancer Therapy Evaluation Program"'
Autor:
Michael Graham Espey, Bhadrasain Vikram, Eric J. Bernhard, Jeffrey C. Buchsbaum, C. Norman Coleman
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:1126-1130
Purpose: In the current molecular-targeted cancer treatment era, many new agents are being developed so that optimizing therapy with a combination of radiation and drugs is complex. The use of emerging laboratory technologies to further biological un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3828e3dde63e8e9449c1ccc5f9778c5c
https://doi.org/10.1016/j.ijrobp.2021.07.1709
https://doi.org/10.1016/j.ijrobp.2021.07.1709
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7620-7628 (2021)
Cancer Medicine
Cancer Medicine
Background Both adolescent and young adult (AYA) and Black or African American (hereafter referred to as Black) cancer patients are historically under‐enrolled in cancer treatment trials (CTT). The purpose of this study was to quantify enrollment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a493e597aeee0c3505d1f9961b31ded7
https://doaj.org/article/8630c65a25c74816984988a11b64ff06
https://doaj.org/article/8630c65a25c74816984988a11b64ff06
Autor:
Christie A Canaria, Frank I. Lin, Jeff Buchsbaum, C. Norman Coleman, Charles A. Kunos, Jacek Capala, Michael Graham Espey, Martin W. Brechbiel, Freddy E. Escorcia, Julie A Hong, Deepa Narayanan
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 49:64-72
Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. This article reviews National Cancer Institute (NCI)’s support of RPT thro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a552194bb0d122f4592d7d39c4b3bd0
https://doi.org/10.1007/s00259-021-05503-z
https://doi.org/10.1007/s00259-021-05503-z
Publikováno v:
Oncotarget
// Aman Chauhan 1 , Tanvir Kabir 2 , Jianrong Wu 3 , Jing Wei 4 , Mary Cook 1 and Charles A. Kunos 5 1 Division of Medical Oncology, University of Kentucky, Lexington, KY, USA 2 College of Medicine, University of Kentucky, Lexington, KY, USA 3 Markey
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0402d8b9344f526a1abc8fc98891313c
https://doi.org/10.18632/oncotarget.27537
https://doi.org/10.18632/oncotarget.27537
Publikováno v:
JNCI: Journal of the National Cancer Institute. 112:128-135
Designing and interpreting single-arm phase II trials of combinations of agents is challenging because it can be difficult, based on historical data, to identify levels of activity for which the combination would be worth pursuing. We identified Canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90216449022e54e30f857c2d9b9b4d01
https://doi.org/10.1093/jnci/djz193
https://doi.org/10.1093/jnci/djz193
Autor:
Arjun Mittra, Elad Sharon, Joanne Kwak-Kim, S. Percy Ivy, Shanda Finnigan, Alice P. Chen, James H Murray, Abdul Rafeh Naqash
Publikováno v:
Oncologist
Despite expanding indications for immunotherapeutic agents, there is limited understanding about their clinical effects on pregnancy outcomes. Generally, pregnant patients with cancer are excluded from clinical trials, and inadvertent pregnancies on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e8786bf928b1d1de373b3a76771e37
https://pubmed.ncbi.nlm.nih.gov/34397143
https://pubmed.ncbi.nlm.nih.gov/34397143
Autor:
Steven H. Lin, Lydia Koi, Andrew S. Liss, Patricia Greninger, Regina K. Egan, Cyril H. Benes, Nathalie Borgeaud, Mechthild Krause, Theodore S. Hong, J. H. Kung, Henning Willers, Irina Korovina, Meredith A. Morgan, Theodore S. Lawrence, Christopher J. Ott, Aliza Rosenkranz, Leslie A. Parsels, Michael Baumann, Beow Y. Yeap, Aaron N. Hata, Lori J. Wirth, Xiao Pan
Publikováno v:
International Journal of Radiation Oncology Biology Physics 111(2021), e63-e74
Int J Radiat Oncol Biol Phys
Int J Radiat Oncol Biol Phys
The development of molecular targeted drugs with radiation and chemotherapy is critically important for improving the outcomes of patients with hard-to-treat, potentially curable cancers. However, too many preclinical studies have not translated into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f0ed32c0a3f4528a9c0083b78ba27c
https://www.hzdr.de/publications/Publ-33980-1
https://www.hzdr.de/publications/Publ-33980-1
Autor:
Kathryn Lurain, Richard F. Little, Howard Streicher, Ravie Kem, Jared C. Foster, Elad Sharon, Joshua E. Reuss, Diana Stern, Ramya Ramaswami, Helen X. Chen
Publikováno v:
JAMA Network Open
Key Points Question Has inclusion of people living with HIV in anti–programmed death 1 and anti–programmed death ligand 1 (anti–PD1/PDL1) immunotherapy trials changed during ongoing Cancer Therapy Evaluation Program advocacy efforts by the Nati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5d3178c756d6e8739d3289f4292bdde
http://europepmc.org/articles/PMC7709086
http://europepmc.org/articles/PMC7709086
Autor:
Rodney Howells, Mark E. Bernard, Aman Chauhan, Charles A. Kunos, Jacek Capala, Riham H. El Khouli, Zin W. Myint
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation. To validate a radiopharmaceutical,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0f276e4ebaded5a3d91331cb2beee56
https://pubmed.ncbi.nlm.nih.gov/33747951
https://pubmed.ncbi.nlm.nih.gov/33747951
Autor:
Charles A. Kunos, Jacek Capala
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 13, Iss 287, p 287 (2020)
Pharmaceuticals, Vol 13, Iss 287, p 287 (2020)
Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ee8f5cca7e6296f6ab379a8c40319dc
http://europepmc.org/articles/PMC7600139
http://europepmc.org/articles/PMC7600139